This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Monday's Health Winners & Losers

Updated from 2:42 p.m. EDT

Clinical updates peppered biotech news Monday, proving positive and negative for some individual stocks but inflicting little consequence on health indices.

Accentia Biopharmaceuticals (ABPI) said that according to data from an ongoing phase III trial for SinuNase, most if not all cases of chronic sinusitis, or CS, are due to fungal-induced inflammation.

SinuNase, Accentia's lead pharmaceutical product, is an intranasal formulation of the antifungal amphotericin B 0.01% suspension. If approved, SinuNase, which has fast-track status from the Food and Drug Administration and is licensed to IMMCO Diagnostics, will be the first therapy available to treat sufferers of CS. Accentia shares gained 27 cents, or 10.8%, to close at $2.76.

Pharmasset (VRUS) said that according to results from a phase I study, its R7128, a candidate for treating chronic hepatitis C, demonstrated potent, dose-dependent antiviral activity across four patient cohorts receiving 750 milligrams or 1500 milligrams once or twice a day for 14 days and was safe and well-tolerated.

Based on the positive results, Pharmasset and its partner Roche said that in late September they plan to start enrolling patients chronically infected with HVC genotype 1 for a 28-day study to determine the safety and tolerability of R7128 in combination with the current standard care of Pegasys plus Copegus. Pharmasset shares rose $1.60, or 15.4%, to close at $12.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
IMCL $5.40 -3.57%
ARIA $8.25 0.00%
ABPI $0.00 0.00%
RGEN $25.78 0.00%
AAPL $126.41 0.00%


DOW 18,135.72 +38.82 0.21%
S&P 500 2,101.04 +2.51 0.12%
NASDAQ 4,982.8090 +15.6680 0.32%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs